Ziopharm Oncology In (ZIOP) 4.94 $ZIOP ZIOPHARM
Post# of 273330
Posted On: 09/03/2016 5:16:23 AM
Ziopharm Oncology In (ZIOP) 4.94 $ZIOP
ZIOPHARM to Present at the 2016 Wells Fargo Healthcare Conference
GlobeNewswire - Wed Aug 31, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 2016 Wells Fargo Healthcare Conference on Wednesday, September 7, 2016 at 10:30 a.m. E.T. The conference is being held at the Westin Boston Waterfront.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04), WFC: 50.55 (+0.12)
Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 4:10PM CDT
Intrexon (XON) reported a loss of 42 cents per share in second-quarter 2016, compared to the year-ago figure of 37 cents.
ZIOP: 4.94 (-0.05), ANIP: 59.86 (-1.56), XON: 25.33 (+0.04)
Intrexon Announces Second Quarter and First Half 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its second quarter and first half financial results for 2016.
ZIOP: 4.94 (-0.05), FCSC: 0.89 (-0.01), XON: 25.33 (+0.04)
ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities
GlobeNewswire - Tue Aug 09, 3:01PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the second quarter ended June 30, 2016, and provided an update on the Company's recent activities.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
Lifshitz & Miller Law Firm Announces Investigation of American Renal Associates Holdings, Inc., CytRx Corporation, El Pollo Loco Holdings, Inc., EndoChoice Holdings, Inc., Full Circle Capital Corporation and ZIOPHARM Oncology, Inc.
PR Newswire - Fri Aug 05, 10:41AM CDT
American Renal Associates Holdings, Inc. (ARA)
AVGR: 4.24 (+0.03), ARA: 21.07 (+0.31), ZIOP: 4.94 (-0.05), FULL: 2.63 (unch), UNH: 136.61 (+0.87), CYTR: 0.57 (-0.01), LOCO: 13.66 (+0.04), GI: 3.89 (unch)
First-In-Human Trials using Non-Viral Sleeping Beauty System to Express CD19-Specific CAR in T cells Published in Journal of Clinical Investigation
GlobeNewswire - Thu Aug 04, 6:00AM CDT
Favorable Long Term Follow-up in Two Trials with Patients Receiving Autologous CAR-T cells and Allogeneic CAR-T cells
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
ZIOPHARM to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Tuesday, August 9, 2016
GlobeNewswire - Tue Aug 02, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it will host a conference call and webcast slide presentation to discuss financial results for the quarter ended June 30, 2016 and provide a mid-year corporate update on Tuesday, August 9, 2016 at 4:30 PM ET.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
ZIOPHARM to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 2:00 p.m. ET. The conference is being held at the Grand Hyatt Hotel in New York City.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Wed May 18, 4:04PM CDT
- Data to be Presented at the 2016 ASCO Annual Meeting -
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
Ziopharm reports 1Q loss
Automated Insights - Tue May 10, 4:28PM CDT
BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Tuesday reported a loss of $12 million in its first quarter.
ZIOP: 4.94 (-0.05)
ZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities
GlobeNewswire - Tue May 10, 4:08PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2016, and provided an update on the Company's recent activities.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
Ignore MannKind Corp.: Here Are 3 Better Stocks
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 25, 9:01AM CDT
Image source: MannKind Corp. I've never seen an independent auditor report so grim as MannKind 's latest. The maker of inhalable insulin Afrezza has been in dire shape ever since marketing partner Sanofi ended their collaboration agreement,...
ZIOP: 4.94 (-0.05), CLDX: 3.35 (-0.01), XON: 25.33 (+0.04), MNKD: 0.74 (unch)
ZIOPHARM Announces Two Oral Presentations at ASGCT 19th Annual Meeting
GlobeNewswire - Mon Apr 18, 11:40AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced results from two programs will be presented in oral sessions at the upcoming 19 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting. The first presentation highlights preclinical data from the Company's novel viral gene therapy candidate for the controlled expression of IL-12 in combination with inhibition of programmed cell death protein 1 (PD-1) in a mouse model of glioma. The second presentation highlights preclinical data from the Company's evolution of the Sleeping Beauty (SB) non-viral transposon-transposase system in a mouse model of leukemia. The ASGCT meeting will take place May 4-7 at the Marriott Wardman Park Hotel in Washington, D.C.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
ZIOPHARM to Present at the Jefferies 2nd Annual Immuno-Oncology Summit
GlobeNewswire - Thu Mar 31, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2 Annual Immuno-Oncology Summit on Thursday, April 7, 2016 at 9:35 a.m. ET. The conference is being held at the Boston Harbor Hotel in Boston, MA.
ZIOP: 4.94 (-0.05)
BUYINS.NET: ZIOP, CROX, CVLT, ANW, HTS, NYMT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Feb 09, 7:10AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Crocs Inc (NASDAQ:CROX), CommVault Systems Inc (NASDAQ:CVLT), Aegean Marine Petroleum Network Inc (NYSE:ANW), Hatteras Financial Corp (NYSE:HTS), New York Mortgage Trust Inc (NASDAQ:NYMT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ANW: 10.29 (+0.10), CROX: 8.52 (+0.03), ZIOP: 4.94 (-0.05), HTS: 16.29 (+0.09), CVLT: 52.25 (+0.13), NYMT: 6.05 (+0.07)
ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies
GlobeNewswire - Tue Feb 09, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor (CAR) modified T-cell therapy in patients with advance lymphoid malignancies. The CD19-specific T cells were modified using the Sleeping Beauty system to stably express the CAR in T cells.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
Waging War on the Greatest Cancer Myth of All
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 07, 8:12AM CST
Image source: National Cancer Institute. In terms of medical diagnoses, there aren't many things scarier than hearing the phrase, "you have cancer." The numbers partially tell the tale. Globally, according to the World Health Organization, there...
ZIOP: 4.94 (-0.05), MRK: 62.98 (+0.08), XON: 25.33 (+0.04), BMY: 56.35 (-0.41)
ZIOPHARM to Present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 02, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 18 Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 1:00 p.m. ET. The conference is being held at the Waldorf Astoria Hotel in New York City.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
Pre-Market Pulse on Biotechnology Stocks -- ZIOPHARM Oncology, BioMarin Pharma, PTC Therapeutics, and Vertex Pharma
ACCESSWIRE - Mon Feb 01, 7:03AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Park Lane Advisor has initiated coverage on the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), PTC Therapeutics Inc. (NASDAQ: PTCT), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free research report on ZIOPHARM Oncology can be accessed at http://www.parklaneadvisor.com/ On Friday, January 29, 2016, the NASDAQ Composite ended at 4,613.95, up 2.38%, the Dow Jones Industrial Average advanced 2.47%, to finish the day at 16,466.30, and the S&P 500 closed at 1,940.24, up 2.48%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
VRTX: 95.11 (+0.36), ZIOP: 4.94 (-0.05), BMRN: 95.73 (+0.54), PTCT: 7.91 (+0.12)
3 Healthcare Technologies That Are Set to Transform Our Lives Over the Next 10 Years
Selena Maranjian, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Sun Jan 31, 10:03AM CST
Photo: Derek Bridges , Flickr Technology seems to change everything, doesn't it? In transportation, for example, innovations such as electric trolleys, automobiles, steam engines, railroads, and airplanes made our travels faster, safer, and more...
EYES: 3.44 (+0.08), ZIOP: 4.94 (-0.05), ZBH: 129.40 (+1.05), XON: 25.33 (+0.04), SYK: 115.60 (+0.37)
ZIOPHARM to Present at the 2016 Wells Fargo Healthcare Conference
GlobeNewswire - Wed Aug 31, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 2016 Wells Fargo Healthcare Conference on Wednesday, September 7, 2016 at 10:30 a.m. E.T. The conference is being held at the Westin Boston Waterfront.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04), WFC: 50.55 (+0.12)
Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 4:10PM CDT
Intrexon (XON) reported a loss of 42 cents per share in second-quarter 2016, compared to the year-ago figure of 37 cents.
ZIOP: 4.94 (-0.05), ANIP: 59.86 (-1.56), XON: 25.33 (+0.04)
Intrexon Announces Second Quarter and First Half 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its second quarter and first half financial results for 2016.
ZIOP: 4.94 (-0.05), FCSC: 0.89 (-0.01), XON: 25.33 (+0.04)
ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities
GlobeNewswire - Tue Aug 09, 3:01PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the second quarter ended June 30, 2016, and provided an update on the Company's recent activities.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
Lifshitz & Miller Law Firm Announces Investigation of American Renal Associates Holdings, Inc., CytRx Corporation, El Pollo Loco Holdings, Inc., EndoChoice Holdings, Inc., Full Circle Capital Corporation and ZIOPHARM Oncology, Inc.
PR Newswire - Fri Aug 05, 10:41AM CDT
American Renal Associates Holdings, Inc. (ARA)
AVGR: 4.24 (+0.03), ARA: 21.07 (+0.31), ZIOP: 4.94 (-0.05), FULL: 2.63 (unch), UNH: 136.61 (+0.87), CYTR: 0.57 (-0.01), LOCO: 13.66 (+0.04), GI: 3.89 (unch)
First-In-Human Trials using Non-Viral Sleeping Beauty System to Express CD19-Specific CAR in T cells Published in Journal of Clinical Investigation
GlobeNewswire - Thu Aug 04, 6:00AM CDT
Favorable Long Term Follow-up in Two Trials with Patients Receiving Autologous CAR-T cells and Allogeneic CAR-T cells
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
ZIOPHARM to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Tuesday, August 9, 2016
GlobeNewswire - Tue Aug 02, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it will host a conference call and webcast slide presentation to discuss financial results for the quarter ended June 30, 2016 and provide a mid-year corporate update on Tuesday, August 9, 2016 at 4:30 PM ET.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
ZIOPHARM to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 2:00 p.m. ET. The conference is being held at the Grand Hyatt Hotel in New York City.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Wed May 18, 4:04PM CDT
- Data to be Presented at the 2016 ASCO Annual Meeting -
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
Ziopharm reports 1Q loss
Automated Insights - Tue May 10, 4:28PM CDT
BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Tuesday reported a loss of $12 million in its first quarter.
ZIOP: 4.94 (-0.05)
ZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities
GlobeNewswire - Tue May 10, 4:08PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2016, and provided an update on the Company's recent activities.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
Ignore MannKind Corp.: Here Are 3 Better Stocks
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 25, 9:01AM CDT
Image source: MannKind Corp. I've never seen an independent auditor report so grim as MannKind 's latest. The maker of inhalable insulin Afrezza has been in dire shape ever since marketing partner Sanofi ended their collaboration agreement,...
ZIOP: 4.94 (-0.05), CLDX: 3.35 (-0.01), XON: 25.33 (+0.04), MNKD: 0.74 (unch)
ZIOPHARM Announces Two Oral Presentations at ASGCT 19th Annual Meeting
GlobeNewswire - Mon Apr 18, 11:40AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced results from two programs will be presented in oral sessions at the upcoming 19 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting. The first presentation highlights preclinical data from the Company's novel viral gene therapy candidate for the controlled expression of IL-12 in combination with inhibition of programmed cell death protein 1 (PD-1) in a mouse model of glioma. The second presentation highlights preclinical data from the Company's evolution of the Sleeping Beauty (SB) non-viral transposon-transposase system in a mouse model of leukemia. The ASGCT meeting will take place May 4-7 at the Marriott Wardman Park Hotel in Washington, D.C.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
ZIOPHARM to Present at the Jefferies 2nd Annual Immuno-Oncology Summit
GlobeNewswire - Thu Mar 31, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2 Annual Immuno-Oncology Summit on Thursday, April 7, 2016 at 9:35 a.m. ET. The conference is being held at the Boston Harbor Hotel in Boston, MA.
ZIOP: 4.94 (-0.05)
BUYINS.NET: ZIOP, CROX, CVLT, ANW, HTS, NYMT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Feb 09, 7:10AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Crocs Inc (NASDAQ:CROX), CommVault Systems Inc (NASDAQ:CVLT), Aegean Marine Petroleum Network Inc (NYSE:ANW), Hatteras Financial Corp (NYSE:HTS), New York Mortgage Trust Inc (NASDAQ:NYMT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ANW: 10.29 (+0.10), CROX: 8.52 (+0.03), ZIOP: 4.94 (-0.05), HTS: 16.29 (+0.09), CVLT: 52.25 (+0.13), NYMT: 6.05 (+0.07)
ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies
GlobeNewswire - Tue Feb 09, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor (CAR) modified T-cell therapy in patients with advance lymphoid malignancies. The CD19-specific T cells were modified using the Sleeping Beauty system to stably express the CAR in T cells.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
Waging War on the Greatest Cancer Myth of All
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 07, 8:12AM CST
Image source: National Cancer Institute. In terms of medical diagnoses, there aren't many things scarier than hearing the phrase, "you have cancer." The numbers partially tell the tale. Globally, according to the World Health Organization, there...
ZIOP: 4.94 (-0.05), MRK: 62.98 (+0.08), XON: 25.33 (+0.04), BMY: 56.35 (-0.41)
ZIOPHARM to Present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 02, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 18 Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 1:00 p.m. ET. The conference is being held at the Waldorf Astoria Hotel in New York City.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
Pre-Market Pulse on Biotechnology Stocks -- ZIOPHARM Oncology, BioMarin Pharma, PTC Therapeutics, and Vertex Pharma
ACCESSWIRE - Mon Feb 01, 7:03AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Park Lane Advisor has initiated coverage on the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), PTC Therapeutics Inc. (NASDAQ: PTCT), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free research report on ZIOPHARM Oncology can be accessed at http://www.parklaneadvisor.com/ On Friday, January 29, 2016, the NASDAQ Composite ended at 4,613.95, up 2.38%, the Dow Jones Industrial Average advanced 2.47%, to finish the day at 16,466.30, and the S&P 500 closed at 1,940.24, up 2.48%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
VRTX: 95.11 (+0.36), ZIOP: 4.94 (-0.05), BMRN: 95.73 (+0.54), PTCT: 7.91 (+0.12)
3 Healthcare Technologies That Are Set to Transform Our Lives Over the Next 10 Years
Selena Maranjian, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Sun Jan 31, 10:03AM CST
Photo: Derek Bridges , Flickr Technology seems to change everything, doesn't it? In transportation, for example, innovations such as electric trolleys, automobiles, steam engines, railroads, and airplanes made our travels faster, safer, and more...
EYES: 3.44 (+0.08), ZIOP: 4.94 (-0.05), ZBH: 129.40 (+1.05), XON: 25.33 (+0.04), SYK: 115.60 (+0.37)
(0)
(0)